Sophiris Bio Inc. (NASDAQ:SPHS) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07

The 2017 Annual Special Meeting of Shareholders (the Annual
Meeting) of Sophiris Bio Inc. (the Company) was held on May 30,
2017. As of April3, 2017, the record date for the Annual Meeting,
30,111,153 shares of common stock were issued and outstanding and
entitled to vote at the Annual Meeting.A summary of the matters
voted upon by shareholders at the Annual Meeting is set forth
below.

Proposal . Election of
Directors

The Companys shareholders elected the six persons listed below as
directors, each to serve until the Companys 2018 Annual Meeting
of Shareholders and until their successors are duly elected and
qualified. The final voting results are as follows:

Proposal . Appointment of Independent
Registered Public Accounting Firm

The Companys shareholders appointed PricewaterhouseCoopers LLP as
the Companys independent registered public accounting firm for
the fiscal year ending December31, 2017. The final voting results
are as follows:

Proposal 3.Approval of
the 2017 Omnibus Incentive Plan

The Companys shareholders failed to approve the adoption of the
2017 Omnibus Incentive Plan. The proposed 2017 Omnibus Incentive
Plan was adopted by the Board subject to shareholder approval in
order to replace the Companys existing 2011 Stock Option Plan.
The 2017 Omnibus Incentive Plan included the latest developments
in plan design for a U.S. based public company, many of which are
missing from the Companys current stock 2011 Stock Option Plan
which was designed to comply with Canadian law and listing
requirements of the Toronto Stock Exchange, which are no longer
applicable to the Company.

The Company believes that its executive officers and other key
personnel currently hold equity awards that help promote pay for
performance and align their interests with those of the
shareholders. Under the terms of the 2011 Stock Option Plan, ten
percent of the issued and outstanding ordinary shares (on a
non-diluted basis) on a particular grant date are available for
issuance under the Plan. There is no assurance that the Plan will
have sufficient shares available for future equity awards
necessary to attract, retain or motivate executive officers,
other employees and consultants and to compensate independent
directors.

The Company will continue to make equity awards under its 2011
Stock Option Plan.

The final voting results are as follow:

About Sophiris Bio Inc. (NASDAQ:SPHS)

Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.

Sophiris Bio Inc. (NASDAQ:SPHS) Recent Trading Information

Sophiris Bio Inc. (NASDAQ:SPHS) closed its last trading session up +0.06 at 2.44 with 161,359 shares trading hands.